SCHEMBL8776230

SCHEMBL8776230

O=C(C1=C(O)C(=O)N(c2ccccn2)C1c1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 10/20 0.56
MEN1 O00255 8/20 0.56
KMT2A Q03164 8/20 0.56
ALDH1A1 P00352 6/20 0.56
PPARG P37231 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
NCOA2 Q15596 1/20 0.54
HIF1A Q16665 1/20 0.54
KDM4E B2RXH2 5/20 0.53
NCOR2 Q9Y618 1/20 0.48
GAA P10253 3/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 1/20 0.46
CCR1 P32246 1/20 0.45
CCR2 P41597 1/20 0.45
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8776240 0.95 RXFP1 (0.53) RXFP1MEN1KMT2AALDH1A1PPARG
SCHEMBL1944068 0.92 RXFP1 (0.58) RXFP1MEN1KMT2AALDH1A1PPARG
SCHEMBL8776214 0.91 RXFP1 (0.54) RXFP1MEN1KMT2AALDH1A1PPARG
SCHEMBL8776183 0.88 MAPT (0.57) RXFP1MEN1KMT2AALDH1A1PPARG
SCHEMBL12852044 0.85 KMT2A (0.62) RXFP1MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL16370909 0.84 GAA (0.64) RXFP1MEN1KMT2AALDH1A1PPARG
SCHEMBL12943326 0.84 RXFP1 (0.55) RXFP1MEN1KMT2AALDH1A1PPARG
SCHEMBL8776252 0.83 RXFP1 (0.48) RXFP1MEN1KMT2AALDH1A1PPARG
SCHEMBL12542346 0.82 ALDH1A1 (0.66) RXFP1MEN1KMT2AALDH1A1PPARG
SCHEMBL16370574 0.82 GAA (0.64) RXFP1MEN1KMT2AALDH1A1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120128630-A1 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE VIVALIS (FR) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120128630-A1 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARAMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE NAT1, POLM, PYGL RXFP1 4001/4885MEN1 4116/4885KMT2A 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.